The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Program -- Prostate Cancer Research Program -- Clinical Trial Award
The intent of the PCRP Clinical Trial Award (CTA) is to accelerate the development of new interventions to decrease the burden of prostate cancer by supporting the rapid implementation of early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II). Therapeutic approaches proposed for testing through the CTA may include novel interventions or the testing of existing interventions for new indications in prostate cancer, but must represent hypothesis-based approaches for the treatment of prostate cancer that will have a major impact on one or more of the FY19 PCRP Overarching Challenges. Interventions may include drugs, devices, biologics, targeted radionuclides, surgical procedures, behavior modifications, or other types of interventions based on investigator discretion. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform prostate cancer patient care.
• Required Pre-Application Deadline: June 27, 2019
• Application Submission Deadline: July 18, 2019
Areas of Interest
The mission of the FY19 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY19 PCRP Overarching Challenges:
• Improve the quality of life for survivors of prostate cancer
• Develop treatments that improve outcomes for men with lethal prostate cancer
• Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
• Define the biology of lethal prostate cancer to reduce death
Independent Investigators at all levels are eligible to be named by the organization as the PI on the application.
The anticipated direct costs budgeted for the entire period of performance for an FY19 PCRP CTA will not exceed $2,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.